Home > News > Recent cases

iSmart Developments v Currentbody.com [2024] EWHC 2889 (IPEC)15 November 2024James Abrahams KC and Henry Edwards appeared for the successful Defendant in the Claimants’ application in each of two related actions to strike out allegations of breach of contract and misuse of confidential information, and alternatively for summary judgment. HHJ Hacon dismissed the applications and held that the Defendant’s case based on alleged breach of […]
Extreme Networks Ltd v Extreme E Ltd [2024] EWCA Civ 138614 November 2024Ashton Chantrielle appeared before the Court of Appeal for the Applicant/Respondent (“Extreme E”) in this second appeal from the UKIPO relating to Extreme E’s trade mark registration for services in Class 41. One of the core issues on appeal was the interpretation of “booking of seats for shows” in Extreme E’s trade mark and its […]
SkyKick UK Ltd v Sky Ltd [2024] UKSC 3613 November 2024Adrian Speck KC appeared for the successful Appellants (“SkyKick”) in the proceedings issued by the Respondents (“Sky”) alleging infringement of several SKY marks, and passing off, by SkyKick’s use of SKYKICK for email migration and cloud storage services. In this landmark decision, the Supreme Court held that the registration of a trade mark can be […]
Kieran Corrigan v Timol [2024] EWCA Civ 123318 October 2024Jonathan Hill appeared for the Appellant, Kieran Corrigan & Co Limited (“KCL”) in its appeal against the decision of Jonathan Hilliard KC (sitting as a Deputy High Court Judge) (“the Judge”) to dismiss claims for breach of confidence against the Respondent (“Mr. Timol”). The claims related to the alleged misuse by a company of which […]
Sandoz AG v Biogen MA Inc [2024] EWHC 2567 (Pat)11 October 2024Michael Tappin KC appeared for the Claimants (Sandoz) and Justin Turner KC appeared for the Defendant (Biogen). Sandoz sought revocation of Biogen’s patent and an Arrow declaration, while Biogen counterclaimed for infringement. Biogen’s patent in suit, EP 967, related to a method for assessing the risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) […]